These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8911880)

  • 1. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
    Ookawara S; Tabei K; Sakurai T; Sakairi Y; Furuya H; Asano Y
    Eur J Clin Pharmacol; 1996; 51(2):149-51. PubMed ID: 8911880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of hyperkalemia caused by nafamostat mesilate.
    Muto S; Imai M; Asano Y
    Gen Pharmacol; 1995 Dec; 26(8):1627-32. PubMed ID: 8745149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.
    Muto S; Imai M; Asano Y
    Br J Pharmacol; 1994 Jan; 111(1):173-8. PubMed ID: 8012693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct.
    Muto S; Imai M; Asano Y
    Br J Pharmacol; 1993 Jul; 109(3):673-8. PubMed ID: 8358565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of nafamostat mesilate on the renin-aldosterone system].
    Okamoto T; Marukawa S; Hayami H; Ozaki K; Ishida H; Kono K
    Masui; 1992 Mar; 41(3):326-30. PubMed ID: 1560570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1237-43. PubMed ID: 11579633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of prostasin secretion by serine protease inhibitors in the kidney.
    Iwashita K; Kitamura K; Narikiyo T; Adachi M; Shiraishi N; Miyoshi T; Nagano J; Tuyen DG; Nonoguchi H; Tomita K
    J Am Soc Nephrol; 2003 Jan; 14(1):11-6. PubMed ID: 12506133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M; Tanaka K; Hiraiwa T; Tanaka K
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
    Lee JK; Ryu JK; Park JK; Lee SH; Yoon WJ; Kim YT; Jung HC; Yoon YB
    Pancreas; 2008 Apr; 36(3):255-60. PubMed ID: 18362838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
    Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
    J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
    Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
    Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.
    Han X; Wang N; Li J; Wang Y; Wang R; Chang J
    Chem Biol Interact; 2019 Jan; 297():80-84. PubMed ID: 30393114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
    Ino Y; Suzuki K; Sato T; Iwaki M
    Nihon Yakurigaku Zasshi; 1986 Dec; 88(6):449-55. PubMed ID: 2435641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.
    Sendo T; Itoh Y; Goromaru T; Sumimura T; Saito M; Aki K; Yano T; Oishi R
    Br J Pharmacol; 2003 Mar; 138(5):959-67. PubMed ID: 12642398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
    Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
    Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
    Mori S; Itoh Y; Shinohata R; Sendo T; Oishi R; Nishibori M
    J Pharmacol Sci; 2003 Aug; 92(4):420-3. PubMed ID: 12939527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
    Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
    J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.